Sentences with phrase «shares at all current prices»

For instance, a company may give an employee the right to buy 100 shares at the current price of $ 10 per share in 1998.

Starboard Value believes that shares at its current price are «deeply undervalued» given shares have under - performed the Russell 2000 index by three percent, 12 percent and 28 percent on a one - year, three - year and five - year basis, respectively.

You sell the borrowed shares at the current price and if the price drops, you make money by buying the shares back at the lower price and then returning them to your investment firm.

Not exact matches

Listed Perth company AnaeCo has announced plans for a $ 21.4 million rights issue pitched at lesss than half its current share price, as it seeks to complete its first waste treatment plant in Shenton

As new financial details are revealed, Uber's shareholders must consider whether to sell shares at the current $ 32.97 - per - share price that SoftBank has offered, or wait for a potential public offering in 2019.

The Instagram story also shows that she was given 995 Adidas (addyy) shares, which would also have a total value of around $ 100,000 at current prices.

Gerstner said he thinks United Airlines stock is worth double or triple its current share price of about $ 75, or even more, with his target price at as much as $ 235 a share.

The lot size rule for Japan shares makes it hard for Nintendo to widen the base of investors at the current price, says Atul Goyal of Jefferies.

HelloFresh sold 31 million new shares in an initial public offering, giving it a valuation around 1.7 billion euros at current prices — more than double the $ 888 million (763 million euro) market capitalization of struggling Blue Apron (aprn).

Still, Fitbit has something of a first - mover advantage that's likely to keep its share price floating at its current level of around $ 32, which is more than 40 percent higher than its trading start price.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

By separating into three independent companies, reducing unnecessary corporate overhead, operating at average industry returns, and buying back stock, AIG can trade at over $ 100 per share — 66 % above its current $ 60 price,» John Paulson, President, Paulson & Co..

With virtually identical market capitalization (the price it would take to buy all shares of a company's outstanding common stock at the current market value), what exactly is an investor in each respective firm getting for his or her money?

The company in August sold 1.5 million unregistered shares to a private investor who is also a current shareholder at a price of $ 2.10 per share, for aggregate consideration of $ 3.15 million.

At its current price of $ 55 / share, HLF has a price to economic book value (PEBV) ratio of 1.4.

At its current valuation of ~ $ 67 / share, HLF has a price to economic book value ratio (price - to - EBV) of 1.2 That ratio means that the market expects only 20 % growth in NOPAT for the remainder of HLF's existence.

The Company's current offering price for its Shares, as well as other information, including information about management and the healthcare - focused investment strategy, are available at http://www.nexpointcapital.com/.

THL Credit pays quarterly dividends of $ 0.27 per share, giving TCRD stock a staggering annual yield of 13.8 % at the current price.

To justify the current price of $ 47 / share, Jarden must grow NOPAT by 13 % compounded annually for the next 16 years, at which point, Jarden would be generating over $ 66 billion in revenue.

The billionaire investor, 79, held 1.41 million Netflix shares as of March 31, according to data compiled by Bloomberg, making the latest sales worth about $ 960 million at current prices.

At its current price of $ 105 / share, HAS has a price - to - economic book value (PEBV) ratio of 1.2.

At its current price of $ 142 / share, CLX has a price - to - economic book value (PEBV) ratio of 1.2.

In 2002, Bezos did give his shares worth $ 500 million at current prices for charitable missions.

With its 19 % ROIC, WU should be valued at $ 31 / share according to Figure 1, 64 % above its current stock price.

Through these schemes, Shkreli obtained over $ 5.6 million in cash and Retrophin shares or the use of Retrophin shares worth over $ 59 million (at current market prices).

Despite the impressive fundamentals, at its current price of $ 66 / share, Wal - Mart has a PEBV ratio of 0.8.

As a result of these agreements, Retrophin paid $ 200,000 in cash and issued 581,000 shares to MSMB investors, resulting in a benefit to Shkreli of over $ 17.3 million (at current market prices), and is embroiled in an arbitration with Rosenfeld in which Rosenfeld is seeking $ 1,650,000.

The consortium of buyers have about four weeks to lock in enough investors at the current share price or to offer a higher price.

Best of all, at its current price of $ 35 / share, Oracle has a price - to - economic book value (PEBV) ratio of 0.9.

(f) by causing Retrophin to enter into the Yaffe Consulting Agreement, as a result of which Retrophin paid $ 200,000 in cash and issued 15,000 shares to Yaffe, resulting in a benefit to Shkreli of more than $ 600,000 (at current market prices).

The shares Shkreli obtained from Su are worth more than $ 3.7 million at current market prices.

As a result of these agreements, Retrophin paid out $ 2.8 million in cash and issued 11,000 Retrophin shares, and Shkreli diverted an additional 47,610 Retrophin shares for the benefit of himself and his MSMB Funds, resulting in a benefit to him and to them of more than $ 4.5 million (at current market prices).1

(i) by causing Retrophin to commence a litigation against Doe in order to coerce Doe into giving Shkreli Doe's Fearnow Shares, and by causing Retrophin to enter into a settlement with Doe whereby Retrophin paid $ 100,000 and Doe delivered 50,000 shares to Shkreli, resulting in a benefit to Shkreli of more than $ 1.4 million (at current market prShares, and by causing Retrophin to enter into a settlement with Doe whereby Retrophin paid $ 100,000 and Doe delivered 50,000 shares to Shkreli, resulting in a benefit to Shkreli of more than $ 1.4 million (at current market prshares to Shkreli, resulting in a benefit to Shkreli of more than $ 1.4 million (at current market prices).

Those shares are worth more than $ 1.4 million at current market prices.

(d) by causing Retrophin to pay cash to himself, Biestek, and Fernandez so that he would not have to invest $ 731,778 of his own funds in the February PIPE, and by using PIPE proceeds in contravention of the terms of the Securities Purchase Agreement to fund investments by Shkreli, Biestek and Fernandez, resulting in an additional benefit to Shkreli alone of $ 360,000 in cash and 180,000 Retrophin shares and warrants worth more than $ 5.3 million (at current market prices).

At its current price of $ 39 / share, Southwest has a price to economic book value (PEBV) ratio of 0.7.

As a result of these agreements, Retrophin paid out $ 200,000 in cash and issued 581,000 Retrophin shares, resulting in a benefit to Shkreli and his MSMB Funds of more than $ 17.3 million (at current market prices).

(j) by causing Retrophin to enter into a settlement with Jackson Su whereby Retrophin paid $ 107,638 and Shkreli received 126,388 shares, resulting in a benefit to Shkreli of more than $ 3.7 million (at current market prices).

At its current price of $ 108 / share, Traveler's has a PEBV ratio of 0.6.

As a result, the 90,000 shares became 450,000 Retrophin shares, and are worth more than $ 13.3 million at current market prices.3 See generally ¶ ¶ 27 - 39, infra.

At its current price of $ 35 / share, CSCO has a price - to - economic book value (PEBV) ratio of 0.9.

At its current price of $ 117 / share, NPK has a price - to - economic book value (PEBV) ratio of 1.0.

At its current price of $ 65 / share, Thor has a price to economic book value (PEBV) ratio of 1.1.

At its current price of $ 41 / share, VIAB has a price to economic book value ratio (PEBV) of 0.5, which implies that the market believes its NOPAT will permanently decline by 50 %.

At its current price of $ 59 / share, TGT has a price - to - economic book value (PEBV) ratio of 0.5.

At its current price of $ 23 / share, KLIC has a price - to - economic book value (PEBV) ratio of 0.7.

It also allows investors to transfer their shares, in the interim, at current property prices through its proprietary secondary sale platform.

Others will stand ready to buy the shares at the current market price, meaning supply and demand aren't helpful ways to think about stock prices.

Returns at public offering price (after sales charge) for class A and class M shares reflect the current maximum initial sales charges of 5.75 % and 3.50 % for equity funds and Putnam Multi-Asset Absolute Return Fund, and 4.00 % and 3.25 % for income funds (1.00 % and 0.75 % for Putnam Floating Rate Income Fund, Putnam Absolute Return 100 Fund, Putnam Fixed Income Absolute Return Fund, and Putnam Short - Term Municipal Income Fund), respectively.

At its current price of $ 14 / share, SCS has a price - to - economic book value (PEBV) ratio of 0.8.